— Several presentations to highlight key aspects of lead product candidate, INO-3107, as a potential treatment for Recurrent RespiratoryPapillomatosis (RRP)
— Additional presentations focus on promise of next-generation DNA medicine technology, including the first preclinical data describing potential for DNA-encoded protein technology (DPROT) to address Hemophilia A
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases,today announced that it will present data at a number of upcoming scientific conferences, highlighting key aspects of lead product candidate INO-3107 for RRP. INOVIO has begun the rolling submission of its Biologics License Application (BLA) for INO-3107, which it anticipates completing in the second half of 2025 with the goal of file acceptance by the U.S. Food and Drug Administration by the end of 2025.
https://mma.prnewswire.com/media/2310866/INOVIO_v1_Logo.jpg
INOVIO also plans to highlight its next-generation DNA-medicine technology, including presentations on a Phase 1 clinical trial of a DNA-encoded monoclonal antibody (DMAb) product candidate and new preclinical data on DPROTs addressing Hemophilia A.
Presentations on INO-3107 for RRP:
American Academy of Otolaryngology – Head and Neck Surgery Annual MeetingIndianapolisDate: October 11-13Poster Title: DNA Immunotherapy (INO-3107) Demonstrates a Durable Response for Treatment of HPV-6/11 Recurrent Respiratory Papillomatosis
World Vaccine Congress EuropeAmsterdam, NLDate: October 13Time: 3:45 PM CESTPresentation Title: Leveraging the Potential of DNA Immunotherapy: Long-Term Efficacy in HPV-6 & 11 Recurrent Respiratory Papillomatosis
European Society For Medical Oncology CongressBerlin, DEDate: October 19Poster Title: DNA Immunotherapy (INO-3107) in HPV-6 & 11 Recurrent Respiratory Papillomatosis – Long-Term Efficacy
37th Annual International Papillomavirus Society ConferenceBangkok, THDate: October 24Time: 2:40 – 2:55 PM ICTPresentation Title: Clinical Response to INO-3107 in RRP is Irrespective of Papilloma Microenvironment and Molecular Subtype
Date: October 25Time: 6:54 – 7:00 PM ICTE-Poster Title: DNA Immunotherapy (INO-3107) Induces Persistent Immune Responses Resulting in Long-term Efficacy Through Post-Treatment Year 2 for HPV 6&11 RRP
International Society for Vaccines Annual CongressStellenbosch, SADate: October 30Time: 10:20 – 10:35 AM SASTPresentation Title: Immunotherapy, INO-3107, is Well-Tolerated, Effective, and Elicits an Antigen-Specific T-cell Response in Adults with HPV-6 & 11 Recurrent Respiratory Papillomatosis
Presentations on Next-Generation DNA Medicine:
European Society of Gene and Cell Therapy CongressSeville, ESDate: October 7-10Poster Title: Employment of the CELLECTRA® in vivo gene delivery platform in a first in human (FIH) DNA encoded monoclonal antibody (DMAb) clinical trial
World Vaccine Congress EuropeAmsterdam, NLDate: October 16Time: 1:00 PMCETPresentation Title: DMAb Technology: Next Generation DNA Medicine Design and Delivery
World Orphan Drug CongressAmsterdam, NLDate: October 29Time: 11:10 AM CETPresentation Title: DMAb Technology: The Transformational Potential of Next Gen DNA Medicine in Rare Disease
14th World Federation of Hemophilia Global ForumMontreal, CADate: November 14Time: 1:45 PM ESTPresentation Title: Novel FVIII Secretion Via Non-Viral Vector DNA Medicine Platform
Available abstracts will be shared on INOVIO's website following presentations.
About INOVIOINOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
ContactsMedia: Jennie Willson, (267) 429-8567, communications@inovio.com Investors: Peter Vozzo – ICR Healthcare, (443) 213-0505,investor.relations@inovio.com
https://edge.prnewswire.com/c/img/favicon.png?sn=PH82778&sd=2025-09-25
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-upcoming-scientific-conferences-302566500.html
SOURCE INOVIO Pharmaceuticals, Inc.
https://rt.newswire.ca/rt.gif?NewsItemId=PH82778&Transmission_Id=202509250805PR_NEWS_USPR_____PH82778&DateId=20250925